These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33757528)

  • 1. Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease.
    Yang X; Chang X; Wu S; Sun X; Zhu X; Wang L; Xu Y; Yao X; Rao S; Hu X; Xia M; Bian H; Yan H; Gao X
    Lipids Health Dis; 2021 Mar; 20(1):27. PubMed ID: 33757528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD.
    Naveau S; Lamouri K; Pourcher G; Njiké-Nakseu M; Ferretti S; Courie R; Tranchart H; Ghinoiu M; Balian A; Prévot S; Perlemuter G; Dagher I
    Obes Surg; 2014 Oct; 24(10):1693-701. PubMed ID: 24841950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation.
    Kumar R; Rastogi A; Sharma MK; Bhatia V; Tyagi P; Sharma P; Garg H; Chandan Kumar KN; Bihari C; Sarin SK
    Dig Dis Sci; 2013 Jan; 58(1):265-74. PubMed ID: 22790906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.
    Cassinotto C; Boursier J; de Lédinghen V; Lebigot J; Lapuyade B; Cales P; Hiriart JB; Michalak S; Bail BL; Cartier V; Mouries A; Oberti F; Fouchard-Hubert I; Vergniol J; Aubé C
    Hepatology; 2016 Jun; 63(6):1817-27. PubMed ID: 26659452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease.
    Lee MS; Bae JM; Joo SK; Woo H; Lee DH; Jung YJ; Kim BG; Lee KL; Kim W
    PLoS One; 2017; 12(11):e0188321. PubMed ID: 29176844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.
    Goyal R; Mallick SR; Mahanta M; Kedia S; Shalimar ; Dhingra R; Sharma H; Das P; Datta Gupta S; Panda S; Acharya SK
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1738-45. PubMed ID: 23808910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one.
    Chuah KH; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1404-1411. PubMed ID: 31907981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages.
    Shi YW; Wang QY; Zhao XY; Sun YM; Kong YY; Ou XJ; Jia JD; Wu SS; You H
    J Dig Dis; 2020 May; 21(5):279-286. PubMed ID: 32336033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan-aspartate aminotransferase to predict severity of liver disease in children.
    Chaidez A; Pan Z; Sundaram SS; Boster J; Lovell M; Sokol RJ; Mack CL
    Hepatol Commun; 2022 Nov; 6(11):3015-3023. PubMed ID: 36069338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis.
    Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2570-2580.e37. PubMed ID: 30876959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.
    Petta S; Vanni E; Bugianesi E; Di Marco V; Cammà C; Cabibi D; Mezzabotta L; Craxì A
    Liver Int; 2015 May; 35(5):1566-73. PubMed ID: 24798049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
    Boursier J; Vergniol J; Guillet A; Hiriart JB; Lannes A; Le Bail B; Michalak S; Chermak F; Bertrais S; Foucher J; Oberti F; Charbonnier M; Fouchard-Hubert I; Rousselet MC; Calès P; de Lédinghen V
    J Hepatol; 2016 Sep; 65(3):570-8. PubMed ID: 27151181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.
    Chan WK; Nik Mustapha NR; Mahadeva S
    Hepatol Int; 2015 Oct; 9(4):594-602. PubMed ID: 25788185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis.
    Corpechot C; Gaouar F; El Naggar A; Kemgang A; Wendum D; Poupon R; Carrat F; Chazouillères O
    Gastroenterology; 2014 Apr; 146(4):970-9; quiz e15-6. PubMed ID: 24389304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease.
    Seki K; Shima T; Oya H; Mitsumoto Y; Mizuno M; Okanoue T
    Hepatol Res; 2017 Aug; 47(9):882-889. PubMed ID: 27753194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.